Abstract
KRAS is mutated in 25% of non-small cell lung cancer (NSCLC) adenocarcinoma, with KRAS G12C and G12V mutations occurring in ∼13% and ∼7% of patients, respectively. Whereas G12C inhibitors (G12Ci) sotorasib (AMG 510) and adagrasib (MRTX849) have demonstrated promising antitumor activity in patients with KRAS G12C mutant (mt) NSCLC, KRAS G12V mt NSCLC remains an unmet need. VS-6766 is a unique dual RAF/MEK inhibitor which has shown single agent activity against KRAS G12V mt NSCLC (Guo Lancet Oncology 2020).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
